On September 18, 2023, Factorial Biotechnologies announced its groundbreaking partnership with Ginkgo Bioworks to revolutionize the field of DNA sequencing. Together, they aim to develop an exceptional isothermal DNA polymerase specifically designed for Factorial’s single-cell next-generation sequencing (NGS) library prep kit.
Factorial Biotechnologies has made significant strides in their in-cell library preparation technology, which eliminates the need for cell isolation during the single-cell library preparation process. This breakthrough allows for the seamless creation of single-cell libraries within a mixed cell population. Furthermore, Factorial has successfully developed an extraction-free sample prep technology that enables the production of single-cell sequencing.
By leveraging their innovative in-cell library preparation technology, Factorial Biotechnologies aims to improve accessibility to single-cell sequencing. This advancement will have a profound impact on the scientific community, as it opens up new possibilities for understanding cellular heterogeneity and unraveling complex biological processes.
In addition to their collaboration with Ginkgo Bioworks, Factorial Biotechnologies has also joined forces with Watchmaker Genomics to further optimize a disruptive technology capable of preparing complete whole genome and RNA libraries. This exciting venture, known as the GenNext™ NGS Library Prep Kit, combines state-of-the-art enzymes and buffers to facilitate the preparation of libraries for illumina® sequencing from fragmented double-stranded DNA and PCR.
The partnership between Factorial Biotechnologies, Ginkgo Bioworks, and Watchmaker Genomics marks a significant milestone in the field of DNA sequencing. With their combined expertise and cutting-edge technologies, they are poised to revolutionize the way researchers study and analyze genetic information. Stay tuned for the remarkable advancements that will unfold as a result of this collaboration.
Ginkgo Bioworks Holdings, Inc.
Updated on: 07/12/2023
Debt to equity ratio: Neutral
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
We did not find social sentiment data for this stock
|Analyst / firm||Rating|
Cowen & Co.
DNA Stock Performance on September 18, 2023: Stable Day with Positive Earnings and Revenue Growth
On September 18, 2023, DNA, a company in the Health Services sector, experienced a relatively stable day in terms of stock performance. The day began with the stock opening at the previous day’s closing price of $1.93. Throughout the day, the stock price fluctuated within a range of $1.90 to $1.97. The trading volume for the day was 846, which is significantly lower than the average volume of 23,348,034 over the past three months. One of the key metrics to consider when evaluating a company’s stock performance is its earnings growth. DNA’s earnings growth for the last year stood at -10.38%, indicating a decline in profitability. However, the company has shown a significant rebound in earnings growth for the current year, with a positive growth rate of +73.18%. In terms of revenue growth, DNA witnessed a substantial increase of +52.21% in the last year. However, it is important to note that DNA’s net profit margin stands at -440.63%. When evaluating a stock, it is also essential to consider valuation metrics. DNA’s P/E ratio is not available (NM), suggesting that the company may not currently have positive earnings or may have negative earnings per share. The price/sales ratio of 5.94 indicates that investors are willing to pay approximately 5.94 times the company’s annual revenue for each share of stock. It is worth noting that no competitor data is available for DNA. Looking ahead, DNA’s next reporting date is scheduled for November 13, 2023. The EPS forecast for this quarter is -$0.08, indicating a projected loss per share. In conclusion, DNA’s stock performance on September 18, 2023, was relatively stable, with the stock trading within a narrow range. The company has shown positive earnings and revenue growth trends, indicating a potential turnaround. However, it is crucial for investors to closely monitor DNA’s financials and upcoming reporting dates to make informed investment decisions.
Ginkgo Bioworks Holdings Inc Shows Positive Stock Performance and Promising Future Growth: Analysts Predict Further Increase
Ginkgo Bioworks Holdings Inc, a leading biotechnology company, has shown positive stock performance on September 18, 2023. Analysts have provided price forecasts indicating further growth in the coming months. The median target price is $3.20, with a high estimate of $12.00 and a low estimate of $1.25. This suggests a potential increase of 66.67% from the last recorded price of $1.92.
The consensus among nine polled investment analysts is to buy stock in Ginkgo Bioworks Holdings Inc. This rating has remained steady since August, indicating strong positive sentiment towards the company’s prospects.
Ginkgo Bioworks Holdings Inc reported earnings per share of -$0.08 for the current quarter, indicating a loss. However, the company’s sales for the same period reached $65.8 million, highlighting its revenue-generating capabilities.
Investors are eagerly awaiting the upcoming reporting date of November 13, when Ginkgo Bioworks Holdings Inc will release more detailed financial information. This will provide further insights into the company’s performance and potentially impact its stock price.
Overall, Ginkgo Bioworks Holdings Inc has shown positive stock performance on September 18, 2023, with analysts predicting further growth. The consensus among investment analysts to buy the stock reflects confidence in the company’s potential. Investors should keep an eye on the upcoming reporting date to gain a deeper understanding of Ginkgo Bioworks Holdings Inc’s financial performance and make informed investment decisions.